Neuropeptide Expression in the Human Trigeminal Nucleus Caudalis and in the Cervical Spinal Cord C1 and C2

Uddman, Rolf; Tajti, János; Hou, Mingyan; Sundler, F.; Edvinsson, Lars

doi:10.1046/j.1468-2982.2002.00324.x

Cited by 108 publications

(95 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preabsorption with the blocking peptides resulted in no immunoreactivity for the antibodies against CLR and RAMP1 in the human or rat trigeminal ganglia, which shows that these antibodies are specific for the epitope they are raised against. Similar controls were conducted for the CGRP antibody; exogenous CGRP blocked the immunoreactions as could be expected and verified before , Uddman et al, 2002.…”

Section: Characterization Of Clr and Ramp1 Antibodiesmentioning

confidence: 62%

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

et al. 2010

View full text Add to dashboard Cite

"Differential distribution of calcitonin gene-related peptide (CGRP) and CGRP receptor components (CLR and RAMP1) in the human trigeminal ganglion."Neuroscience, 2010, Jun 2 http://dx.doi.org/10.1016/j.neuroscience.2010.05.016Access to the published version may require journal subscription.Published with permission from: Elsevier Antibodies against purified CLR and RAMP1 proteins were produced and characterized for this study. Trigeminal ganglia were obtained at autopsy from adult subjects and sections from rat trigeminal ganglia were used to compare the immunostaining pattern. The number of cells expressing CGRP, CLR and RAMP1, respectively, were counted. In addition, the glial cells of trigeminal ganglion, particularly the satellite glial cell, were studied to understand a possible relation.We observed immunoreactivity for CGRP, CLR and RAMP1, in the human trigeminal ganglion: 49% of the neurons expressed CGRP, 37% CLR and 36% RAMP1. Co-localization of CGRP and the receptor components was rarely found. There were no CGRP immunoreactions in the glial cells; however some of the glial cells displayed CLR and RAMP1 immunoreactivity. Similar results were observed in rat trigeminal ganglia.We report that human and rat trigeminal neurons store CGRP, CLR and RAMP1, however, CGRP and CLR/RAMP1 do not co-localize regularly but are found in separate neurons. Glial cells also contain the CGRP receptor components but not CGRP. Our results indicate, for the first time, the possibility of CGRP signaling in the human trigeminal ganglion involving both neurons and satellite glial cells. This suggests a possible site of action for the novel CGRP receptor antagonists in migraine therapy.

show abstract

Section: Characterization Of Clr and Ramp1 Antibodiesmentioning

confidence: 62%

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

et al. 2010

View full text Add to dashboard Cite

show abstract

“…PACAP immunoreactivity is present in the human TNC, 18 but is also found in cell bodies of the brain stem locus coeruleus, 50 which projects to the TNC 51 and is reported to be activated during spontaneous migraine attacks. 52 Animal experimental models have proposed that PACAP might have a role in central pain transmission.…”

Section: The Central Actions Of Pacapmentioning

confidence: 99%

“…[13][14][15][16] PACAP has been identified in human sensory 17 and parasympathetic 4 ganglia, as well as in second-order neurons of the trigeminal nucleus caudalis (TNC). 18 The N-terminal 28 amino acids of PACAP-38 share 68% homology with VIP, 19 and the two related peptides are colocalized in rat parasympathetic ganglia. 5,20 The action of PACAP is mediated through three Gprotein coupled receptors: VPAC 1 and VPAC 2 , which have an equally high affinity for PACAP and VIP, and PAC 1 , which has a 1000-fold higher affinity for PACAP than for VIP.…”

mentioning

confidence: 99%

The PACAP Receptor: A Novel Target for Migraine Treatment

2010

View full text Add to dashboard Cite

Summary:The origin of migraine pain has not yet been clarified, but accumulating data point to neuropeptides present in the perivascular space of cranial vessels as important mediators of nociceptive input during migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is present in sensory trigeminal neurons and may modulate nociception at different levels of the nervous system. Human experimental studies have shown that PACAP-38 infusion induces marked dilatation of extracerebral vessels and delayed migraine-like attacks in migraine patients. PACAP selectively activates the PAC 1 receptor, which suggests a possible signaling pathway implicated in migraine pain. This review summarizes the current evidence supporting the involvement of PACAP in migraine pathophysiology and the PAC 1 receptor as a possible novel target for migraine treatment.

show abstract

“…PACAP can be found in human trigeminocervical complex, 6 in the trigeminal and sphenopalatine ganglia. 21 Modulation of PAC 1 and VPAC receptors can inhibit trigeminovascular second order transmission.…”

Section: Discussionmentioning

confidence: 98%

Pituitary Adenylate Cyclase-Activating Polypeptide1 (PACAP)

2009

Encyclopedia of Neuroscience

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating peptide (PACAP) is found in human trigeminocervical complex and can trigger migraine. PACAP levels were measured using a sensitive radioimmunoassay. Stimulation of the superior sagittal sinus (SSS) in cat elevated PACAP levels in cranial blood. Patients with moderate or severe migraine headache had elevated PACAP in the external jugular vein during headache (n = 15), that was reduced 1 h after treatment with sumatriptan 6 mg (n = 11), and further reduced interictally (n = 9). The data suggest PA-CAP, or its receptors, are a promising target for migraine therapeutics.

show abstract

Neuropeptide Expression in the Human Trigeminal Nucleus Caudalis and in the Cervical Spinal Cord C1 and C2

Cited by 108 publications

References 30 publications

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion

The PACAP Receptor: A Novel Target for Migraine Treatment

Pituitary Adenylate Cyclase-Activating Polypeptide1 (PACAP)

Contact Info

Product

Resources

About